Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3…

By W. Cefalu, Lawrence A Leiter, K. Yoon, P. Arias, G. Meininger. The Lancet, 2013

649 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2014, background): “Side effects of SGLT2 inhibitor therapy include genital mycotic infections, at rates of about 11% higher in women and about 4% higher in men compared with placebo (17); in some studies, a slight increase in urinary tract infections was shown (7,9,12,17,18).”
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies (2011, positive): “Moreover, SGLT2 inhibitors have also been reported to reduce other CV risk markers such as visceral fat mass [20,21] and proteinuria [22].”
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015, result): “Side effects of SGLT2 inhibitor therapy include genital mycotic infections, at rates of about 11% higher in women and about 4% higher in men compared with placebo [17]; in some studies, a slight increase in urinary tract infections was shown [7, 9, 12, 17, 18].”
Update on the treatment of type 2 diabetes mellitus. (2016, background): “149] .”